Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth
Open Access
- 1 February 2023
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 42 (12) , 926-937
Abstract
Prostate cancer is the most common cancer in men and it is estimated that over 350,000 men worldwide die of prostate cancer every year. There remains an unmet clinical need to improve how clinically significant prostate cancer is diagnosed and develop new treatments for advanced disease. Aberrant glycosylation is a hallmark of cancer implicated in tumour growth, metastasis, and immune evasion. One of the key drivers of aberrant glycosylation is the dysregulated expression of glycosylation enzymes within the cancer cell. Here, we demonstrate using multiple independent clinical cohorts that the glycosyltransferase enzyme GALNT7 is upregulated in prostate cancer tissue. We show GALNT7 can identify men with prostate cancer, using urine and blood samples, with improved diagnostic accuracy than serum PSA alone. We also show that GALNT7 levels remain high in progression to castrate-resistant disease, and using in vitro and in vivo models, reveal that GALNT7 promotes prostate tumour growth. Mechanistically, GALNT7 can modify O-glycosylation in prostate cancer cells and correlates with cell cycle and immune signalling pathways. Our study provides a new biomarker to aid the diagnosis of clinically significant disease and cements GALNT7-mediated O-glycosylation as an important driver of prostate cancer progression.Keywords
All Related Versions
Funding Information
- Prostate Cancer UK (RIA16-ST2-011, TLD-PF19-002)
- J.G.W. Patterson Foundation
- Prostate Cancer Research and The Mark Foundation
This publication has 80 references indexed in Scilit:
- Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation TherapyEuropean Urology, 2014
- Deubiquitinating Enzyme Usp12 Is a Novel Co-activator of the Androgen ReceptorJournal of Biological Chemistry, 2013
- Precision mapping of the human O‐GalNAc glycoproteome through SimpleCell technologyThe EMBO Journal, 2013
- Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene familyGlycobiology, 2011
- MSnbase-an R/Bioconductor package for isobaric tagged mass spectrometry data visualization, processing and quantitationBioinformatics, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Tn Glycosylation of the MUC6 Protein Modulates Its Immunogenicity and Promotes the Induction of Th17-biased T Cell ResponsesJournal of Biological Chemistry, 2011
- Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccinesMolecular Cancer Therapeutics, 2009
- Observer variation in immunohistochemical analysis of protein expression, time for a change?Histopathology, 2006
- Fully Synthetic Carbohydrate-Based Vaccines in Biochemically Relapsed Prostate Cancer: Clinical Trial Results With α-N-Acetylgalactosamine-O-Serine/Threonine Conjugate VaccineJournal of Clinical Oncology, 2003